1 1 1 l e t t e r s Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks. In individuals with panic disorder there is evidence of decreased central -aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate 1-3 . In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses 4-9 . The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin) 10 , which have a crucial role in arousal 10,11 , vigilance 10 and central autonomic mobilization 12 , all of which are key components of panic. Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses. Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety. Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.
Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks. In individuals with panic disorder there is evidence of decreased central -aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate [1] [2] [3] . In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses [4] [5] [6] [7] [8] [9] . The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin) 10 , which have a crucial role in arousal 10,11 , vigilance 10 and central autonomic mobilization 12 , all of which are key components of panic. Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses. Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety. Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.
Panic disorder is characterized by recurrent episodes of severe anxiety accompanied by multiple physical symptoms such as increased cardio respiratory responses 13 , and it constitutes a risk factor for suicidal behavior 3 . Panic attacks characterized by sudden onset of fear along with rapid increases in respiration and heart rates 14 can reliably be induced in individuals with panic disorder by specific and normally innocuous interoceptive stimuli (for example, intravenous 0.5 M sodium lactate or yohimbine [14] [15] [16] or 7% CO 2 inhalation 17 ). This sug gests that global neural pathways that modulate arousal are perturbed in such subjects. Consistent with this, reduced central GABAergic activity has been reported in subjects with panic disorder 1 , and drugs that restore GABAergic inhibition (for example, benzodiazepines) are clinically effective treatments 2 . In rats, acute disruption of GABAergic inhibition in panicgenerating central nervous system sites such as the dorsomedialperifornical hypothalamus, the amygdala or the dorsal periaqueductal gray leads to paniclike behavior and increased cardiorespiratory responses 18 . Furthermore, after chronically inhibit ing GABA synthesis in the dorsomedialperifornical hypothalamus of rats (with 5 d of local infusions of lallylglycine, a GABA synthesis inhibitor, with osmotic minipumps connected to a cannula), sodium lactate challenges produce anxiety (measured by social interaction, elevated plus maze, openfield test and freezing in defensive probe bury ing test) as well as panic (defined as increased 'flight'like locomotion and increased heart rate and mean arterial pressure (MAP) responses) [4] [5] [6] [7] [8] [9] . The rat panic model used here is also pharmacologically validated with antipanic drugs such as alprazolam 8 and provides a robust model of human sodium lactate-induced panic attacks.
Coincidentally, ORXproducing neurons are exclusive to the dorso medialperifornical and lateral hypothalami 10, 19 and are known to reg ulate feeding, wakefulness 10, 11 and vigilance 10 . The ORXsynthesizing neurons are also involved in mobilizing sympathetic responses and desensitizing the parasympathetically mediated baroreflex 12 to permit simultaneous increases of blood pressure and heart rate 5 , which are all key components of panic. Autonomic nervous system targets of ORX synthesizing neurons are also activated by sodium lactate infusions in the above described sodium lactate-induced panicprone rats but not in controls 5 . Furthermore, mice lacking the Hcrt gene have attenu ated defense responses to panic cues and cardioexcitatory responses after disinhibition of the dorsomedialperifornical hypothalamus 20 . On the basis of these data, we hypothesized that the ORX system has a crucial role in producing panic attacks.
Using our established rat panic model [4] [5] [6] [7] [8] [9] (details in the Online Methods and Supplementary Methods), we first observed that ORXpositive cells (specifically those in the dorsomedialperifornical hypothalamus) are selectively ( Supplementary Fig. 1 ) activated (that is, they expressed the oncoprotein cFos) after sodium lactate admin istration in panicprone rats (P = 0.001, Fig. 1a ), and this activation correlated with an increase in anxietyrelated behavior ( Fig. 1a) .
We next determined whether sodium lactate-induced panic responses are dependent on translation of the Hcrt gene that produces preproORX messenger RNA by injecting siRNA targeting the preproORX mRNA (siORX) into the dorsomedialperifornical hypothalamus of panicprone rats 48 h before sodium lactate or saline challenges ( Fig. 1b-e ). We used quantitative RTPCR to assess mRNA levels in the combined dorsomedial and lateral hypothalamus. Notably, injecting panicprone rats with siORX attenuated multiple components of the sodium lactate-induced paniclike responses, 1 1 2 volume 16 | number 1 | january 2010 nature medicine l e t t e r s including anxietylike behavior (P = 0.035, Fig. 1b ), and cardio excitatory effects (heart rate, P = 0.002; MAP, P = 0.003, Fig. 1d,e ), whereas rats treated with control siRNA (siCON) showed the pre dicted paniclike responses ( Fig. 1b-e ). As expected, treatment with siORX markedly lowered local preproORX mRNA expression in con trol (P = 0.047, Fig. 1f ,g) and panicprone rats compared to treat ment with siCON (P = 0.025, Fig. 1h , also Fig. 1f and Supplementary  Table 1 ). The effect was selective, as neither prodynorphin mRNA (a gene product concurrently expressed in ORXsynthesizing neurons 21 ; P = 0.184, Fig. 1i ) nor local proopiomelanocortin mRNA (P = 0.207, Fig. 1j ) concentrations were lowered by siORX injection. Of note, once a paniclike response occurred, both preproORX (P = 0.007, Fig. 1g ) and prodynorphin (P = 0.001, Fig. 1i ) mRNA levels were rapidly suppressed, suggesting panicinduced negative feedback.
Next, we wanted to determine whether sodium lactate-induced panic in panicprone rats is attenuated by systemic pretreatment with ORX1 receptor antagonists. The selective ORX1 receptor antagonist (SB334867, 30 mg per kg body weight 22 ) attenuated the anxiety like behavior, as measured by social interaction (P = 0.001, Fig. 2a ) and openfield (0.025, Fig. 2b) tests. This ORX1 receptor antagonist also blocked the increases in locomotion (P = 0.017, Fig. 2a ), heart rate (P = 0.001, Fig. 2a ) and blood pressure (P = 0.001, Fig. 2a ; P = 0.001, Fig. 2b ) responses induced by the sodium lactate challenge. These effects mimicked the effects of pretreating panicprone rats l e t t e r s with alprazolam (3 mg per kg body weight ( Fig. 2a) ), a clinically effective benzodiazepine that blocks both spontaneous and sodium lactate-induced panic attacks in individuals with panic disorder 15, 16 . Similarly, a second ORX1 receptor antagonist (SB408124, 30 mg per kg body weight) also attenuated the sodium lactate-induced increases in locomotor activity (P = 0.004, Fig. 2c ) and tachycardia responses (P = 0.001, Fig. 2c ) in another group of panicprone rats (Supplementary Fig. 2a-c shows the location of infusion sites). The SB334867 ORX1 antagonist did not alter anxiety or cardiovascular responses in control rats (n = 7 per group, Supplementary Fig. 3 ) or baseline measures in panicprone rats (Supplementary Results).
One potential concern is that blocking ORX function might induce general somnolence or narcoleptic behavior 10 , thus reducing sodium lactate-induced panic responses. We do not believe this to be the case because in a previous study acute blockade of ORX receptors did not result in narcoleptic states 11 , and reducing ORX activity for short periods with either ORX1 receptor antagonists ( Fig. 2a-c) or gene silencing (Fig. 1c ) did not result in somnolence during testing and did not alter baseline locomotor activity. In fact, silencing the gene encoding ORX or treatment with ORX1 receptor antagonist increased social interaction (Fig. 1b, 2a) and exploration in the open field ( Fig. 2b) , clearly arguing against induction of sedation. The ORX1 receptor antagonist (SB334867, 30 mg per kg body weight intraperitoneally (i.p.)), in addition to its attenuation of paniclike responses, also blocks sodium lactate-induced freezing (indicative of paniclike fear) observed in the defensive burying test in panicprone rats (P = 0.021, Fig. 3a) . Again, this is not due to sedative effects of the ORX1 antagonist, as the number of midline crossings was not reduced in the treated panicprone rats (Fig. 3b) .
Sodium lactate-induced anxiety, but not the cardiorespiratory components of the panic response, seems to be pivotally linked to the bed nucleus of the stria terminalis 23 (Supplementary Fig. 4 shows hypothetical mapping of implicated neural pathways). Therefore, to confirm an end target effect of activating ORXsynthesizing neurons, we focused on the bed nucleus of stria terminalis, which receives ORX projections from the dorsomedialperifornical hypothalamus 10 . Before the sodium lactate challenge, we injected an ORX1 receptor antagonist (SB334867) ipsilaterally into the bed nucleus of the stria terminalis of panicprone rats, which reduced anxietylike behav ior compared to the vehicleinjected rats (P = 0.0002, Fig. 3c and Supplementary Fig. 2d ).
The rat model of panic disorder used here was established over the last 10 years and has a robust face, predictive and construct validity [4] [5] [6] [7] [8] [9] . The model's predictive validity is demonstrated by responses, similar to those observed in humans with panic disorder, to both panicinducing agents (for example, sodium lactate, yohimbine and inhalation of CO 2 ) and therapeutic agents, such as alprazolam and group II metabotropic glutamate agonists, that have antipanic effects 8 . Also, this rat panic model was recently used in a series of preclinical studies to identify a unique class of translocator protein agonist (that enhances the central inhibitory effects of GABA), which subsequently showed antipanic properties in clinical trials, further strengthening the panic model's predictive validity 24 . The construct validity of this model is supported by the fact that neural circuits of the dorsomedialperifornical hypothalamus regulate behavioral and autonomic components of the 'fightorflight' response in rats 25 and are implicated in eliciting paniclike responses in humans 26 and animals 23 . Furthermore, individuals with panic disorder have shown deficits in central GABA activity 1 , and pharmacological restoration of central GABA activity prevents panic attacks 2 , in accordance with our rat model. Also, the panic and anxietylike responses observed in this model are probably not due to a general increase in arousal, as there are no changes in baseline acoustic startle responses ( Supplementary  Fig. 5) . Similarly, there is no increase in baseline startle response in humans with panic disorder 27, 28 .
To clinically validate the role of ORX in panic disorder, we collected cerebrospinal fluid (CSF) samples from 53 medicationfree subjects who presented with suicidal behavior. We assessed the subjects for present symptoms of panic anxiety (as measured by the comprehen sive neuropsychopathological rating scale (CPRS)), and we assayed CSF samples for ORX abundance. We observed a high CSF ORX concentration in subjects with panic anxiety compared to subjects without panic anxiety (Fig. 4) . Furthermore, subjects with only panic anxiety had a significantly higher CSF ORX concentration than sub jects with panic anxiety and comorbid major depressive disorder (P = 0.004, Fig. 4 and Supplementary Table 2 ). Our findings of high ORX concentration in subjects with panic anxiety are consistent with a previous report that chronic treatment with sertraline, a wellknown antipanic and antidepressant drug, lowers ORX concentrations in the CSF, whereas bupropion, an antidepressant with a lower efficacy in treating panic disorder, does not 29 .
Taken together, our translational experiments in a rat panic model and in humans suggest that aberrant functioning of the ORX system may underlie panic attacks. We suggest that ORX1 receptor anta gonists may provide a new therapeutic approach for the treatment of panic disorder.
MeTHOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
Figure 3
Further validation of an ORX antagonist on anxiety and panic associated behavior in the rat panic model. (a-c) Assessment of defensive shock associated behaviors in panic-prone rats (l-AG treated) challenged with isotonic saline (sal) or hypertonic sodium lactate with a prior intraperitoneal injection of either a vehicle (veh) or an ORX-1 receptor antagonist (30 mg per kg body weight SB334868 (SB33)). (a,b) Duration of freezing, near probe (see gray shaded area in defensive shock cage illustration in inset) grooming and burying (a) and number of line crossings (see dashed line in illustration inset in a) (b). * indicates significant differences compared to all other groups using Tukey's HSD test with P < 0.05. (c) Effects of unilateral injections of the ORX-1 receptor antagonist SB334867 (300 pmoles per 100 nl) into the bed nucleus of the stria terminalis (BNST) of l-AG-treated rats, before a sodium lactate challenge, on the duration of SI (compared to SI duration after vehicle injection). Data represent means ± s.e.m. * indicates significant differences between groups using a paired t test with P < 0.05. Supplementary Figure 1d shows l-AG infusion placement verification in DMH-PeF and injections sites into the BNST. Results of the human translational study. Bar graph illustrates ORX concentrations in CSF (obtained by lumbar puncture) samples from all subjects, which were assayed with a radioimmunoassay 30 . A cohort of subjects who presented with acute suicidal behavior was systematically assessed for psychiatric symptoms using the CPRS, where item 3 (inner tension) assesses panic anxiety. A total of 53 medication-free subjects were included comprising three groups: subjects with panic anxiety without major depressive disorder (MDD) (n = 12), subjects with both panic and co-morbid MDD (n = 13) and subjects without panic, without MDD (n = 28). * indicates significant differences between other groups, by Kruskall-Wallis analysis of variance (ANOVA) (P = 0.004) and two-tailed Mann-Whitney U test (subjects with panic and MDD, P = 0.002; subjects without panic, P = 0.01). Data represent means ± s.d. Supplementary Inducing panic-prone state in rats and panic response with sodium lactate. We directed cannulae (Plastics One) at the dorsomedialperifornical hypothala mus 31 and connected them to an osmotic minipump (DURECT Corporation) filled with lallylglycine solution (a glutamic acid decarboxylase inhibitor) or, when applicable, dallylglycine (the inactive isomer of lallylglycine, Sigma). We surgically implanted radiotelemetry probes (Data Science International) into the abdomen of rats 32 to measure cardiovascular and locomotor responses. Rats received i.v. infusions (similarly to clinical studies 16 ; 10 ml over 15 min) of either 0.5 M sodium lactate or 0.9% isotonic saline at least 5 d after the initiation of lallylglycine or dallylglycine infusions.
c-Fos induction in ORX-synthesizing neurons after infusions of sodium lactate or saline. lallylglycine-or dallylglycine-treated rats received sodium lactate or saline challenge (n = 6 per group for four groups) and were imme diately tested in the social interaction test. We perfused the rats 90 min after the social interaction and immunoprocessed their brains into six parallel sets of coronal sections (30 µm).
Injections of siORX or siCON into the combined dorsomedial-lateral hypothalamus of panic-prone rats.
We gave control rats stereotaxic injections of OnTargetPlus SmartPool siRNA against rat preproORX mRNA (siORX, 100 nM, Dharmacon) into one side of the dorsomedialperifornical hypothalamus and negative control siRNA (siCON, 100 nM, Dharmacon) into the other side to confirm gene silencing. We gave panicprone rats bilateral siORX or siCON treatment and 48 h later infused them with saline or sodium lactate (siCON + saline n = 4, siORX plus saline n = 6, siCON plus sodium lactate n = 5, siORX plus sodium lactate n = 6). We recorded social interaction and cardiovascular responses and processed tissue for RTPCR.
Attenuating panic-like responses with systemic ORX-1 receptor antagonists.
We gave panicprone rats i.p. injections of drug or vehicle 30 min before we gave them i.v. infusions and assessed paniclike responses. We injected rats with the ORX1 receptor antagonist SB334867 (30 mg per kg body weight, Tocris, in 0.2 ml, n = 12), alprazolam (3 mg per kg body weight, Sigma, n = 6) or 0.2 ml of 10% dimethyl sulfoxide (n = 11) 30 min before sodium lactate challenge and the social interaction test to assess anxiety behavior. In the second experiment, we used an openfield test to assess anxiety (i.p. vehicle plus i.v. saline (n = 5), i.p. vehicle plus i.v. sodium lactate (n = 5) or i.p. SB334867 (30 mg per kg body weight) plus i.v. sodium lactate (n = 6). In a final experiment, we gave panicprone rats an i.p. injection of an alternative ORX1 receptor antagonist (30 mg per kg body weight SB408124, Tocris, n = 4) or vehicle (0.2 ml, n = 6) 30 min before sodium lactate.
Sodium lactate effects on unconditioned defensive shock-associated behaviors.
We acclimated rats to the testing apparatus for 10 min with a deactivated shock probe. On testing day, we gave panicprone rats an i.p. injection of either the ORX1 receptor antagonist SB334867 (30 mg per kg body weight, n = 3) or vehicle (0.2 ml, n = 6) 30 min before the i.v. challenge. lallylglycine-treated rats were put into three groups where they were further treated with vehicle plus saline (n = 3), vehicle plus sodium lactate (n = 3) or SB334867 plus sodium lactate (n = 3). After intravenous infusions, we then immediately placed the rats in the test cage with activated shock probe (0.7 mA, Lafayette Instruments) for 10 min. We later assessed the time spent burying, in proximity to the probe, grooming and freezing and the number of center crossings 33 .
ORX-1 receptor antagonist into the bed nucleus of the stria terminalis of rats. We gave two of the panicprone rats unilateral injections of SB334867 (300 pmoles per 100 nl vehicle) and the other three a vehicle directed at the bed nucleus of the stria terminalis (using a 33gauge injector (Plastics One)) 30 min before we gave them i.v. infusions of 0.5 M sodium lactate. We conducted a social interaction test after the lactate challenge. We ran the experiment again 48 h later, except the rats that received vehicle received the SB334867 drug and the rats that received the SB334867 drug received the vehicle, so that there was an n = 5 per group.
Measuring ORX type A in the cerebrospinal fluid of subjects with and without panic anxiety. We systematically assessed subjects (n = 53) who presented in acute suicidal crisis for psychiatric symptoms using the CPRS. We used a threshold cutoff of 1.5 on item 3 (panic, inner tension) on that scale to define a subject as having substantial panic symptoms. We performed lumbar punc tures to collect CSF 30 , and we stored samples at −80 °C. We measured CSF ORXA concentrations in duplicate using an 125 I radioimmunoassay (Phoenix Pharmaceuticals). We excluded all subjects with substance abuse and traces of medication in the blood from the analysis. This study was approved by the Lund University Medical Ethics Committee, who gave their informed consent.
Additional methods. Detailed methodology is described in the Supplementary Methods.
Statistical analyses. All values are expressed as means ± s.e.m. or means ± s.d., as noted. Where appropriate, we assessed betweengroups effects by paired or unpaired t tests for two groups and ANOVA with Tukey's HSD post hoc test for more than two groups. We used a nonparametric KruskalWallis ANOVA test for the openfield test because of unequal variance and for clinical data. We assessed withingroups effects with a onetailed Dunnet's test. We set the alpha level at < 0.05 in all cases. We used Microsoft Excel 2007, SPSS 16.0 and Systat 5.0 to analyze data and SigmaPlot 8.0 and CorelDraw 12.0 to plot and illustrate data.
